Escitalopram continuation treatment
prevents relapse of depressive episodes

by
Rapaport MH, Bose A, Zheng H.
Department of Psychiatry,
Cedars-Sinai Medical Center,
Los Angeles, Calif. (Dr. Rapaport);
and Forest Research Institute,
Forest Laboratories, New York, N.Y.
(Drs. Bose and Zheng).
J Clin Psychiatry. 2004 Jan; 65(1): 44-9.


ABSTRACT

BACKGROUND: Current guidelines for antidepressant use recommend 4 to 6 months of continuation treatment to prevent relapse of depression following symptom resolution. This study evaluates the efficacy and safety of continuation escitalopram treatment. METHOD: Outpatients diagnosed with DSM-IV major depressive disorder (male or female, aged 18 to 81 years) who had completed 8 weeks of randomized double-blind treatment with escitalopram, citalopram, or placebo entered an 8-week flexible-dose, open-label phase in which all patients received escitalopram (10-20 mg/day). This study was initiated November 3, 1999, and completed April 5, 2001. Patients who met responder criteria (score of /= 22 or discontinuation due to an insufficient therapeutic response) from the start of the double-blind treatment phase. RESULTS: A total of 502 patients received open-label escitalopram treatment and had at least 1 MADRS assessment. A total of 274 evaluable subjects entered the double-blind treatment phase; 93 received placebo and 181 received escitalopram. Time to depression relapse was significantly longer (p =.013) and the cumulative rate of relapse was significantly lower in patients who received escitalopram (26% escitalopram vs. 40% placebo; hazard ratio = 0.56; p =.01). Escitalopram-treated subjects had significantly lower depression ratings than those of placebo-treated patients. Escitalopram continuation treatment was safe and well tolerated. Discontinuation rates due to adverse events were 7% for the placebo group and 4% for the escitalopram-treated group. CONCLUSION: Continuation treatment with escitalopram is effective in preventing relapse into an episode of major depressive disorder.
Escitalopram (Lexapro)
Citalopram and ecstasy
SSRIs and panic disorder
Citalopram and selegiline
Citalopram v amitriptyline
Citalopram and depression
Citalopram and panic disorder
Serotonin and romantic lovers
Escitalopram (Lexapro) : profile
Citalopram maintenance therapy
Citalopram and depression: trials
Big Pharma meets Madison Avenue
Citalopram: oral versus intravenous
Serotonin and the genetics of depression
Escitalopram (Lexapro, Cipralex): a review (2009)
Single isomer SSRI escitalopram as an antidepressant
Escitalopram (Lexapro): mechanism of antidepressant action